Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum

Core Insights - Pelthos Therapeutics Inc. has launched the "Moms Against Molluscum" movement to support families dealing with molluscum contagiosum, a highly contagious skin infection affecting millions, particularly children [1][8]. Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on developing innovative therapeutic products for unmet patient needs, with its lead product being ZELSUVMI™ (berdazimer) topical gel, approved for treating molluscum contagiosum [13]. Product Information - ZELSUVMI is a topical nitric oxide-releasing gel, effective for treating molluscum in patients aged one year and older, and is the first FDA-approved at-home treatment for this condition [4][10]. - The product was launched in July 2025 and is designed for convenient application, allowing treatment at home or on-the-go [4][10]. Market Context - Molluscum contagiosum affects an estimated 16.7 million people in the U.S., with around 6 million new cases annually, primarily among children [2][7]. - Approximately 41% of children with molluscum will transmit the infection to others in their household, highlighting the need for effective treatment options [2]. Community Engagement - The "Moms Against Molluscum" movement aims to empower families to share their experiences and educate them about new treatment options, fostering a supportive community [5][6]. - Pelthos is actively promoting this initiative through social media to raise awareness and encourage discussions about molluscum contagiosum [6].